When does Opdivo’s patent exclusivity end in the U.S.?
Patent “exclusivity” for a brand drug can mean different things (a blocking patent vs. a marketing exclusivity period). The information provided here doesn’t specify the exact Opdivo patent(s) or the specific exclusivity type you mean, so I can’t give a single definitive date.
If you want, tell me whether you mean:
- the date the last relevant U.S. patent listed on Opdivo ends, or
- the end of regulatory exclusivity (like FDA exclusivity periods), or
- the date a biosimilar could enter under FDA pathways.
What to check to get the exact end date
The most reliable way to pinpoint Opdivo’s end of exclusivity is to look up the specific U.S. patents tied to Opdivo and see which one has the latest expiration date, including any listed extensions or listed “Orange Book” patents. A practical starting point is DrugPatentWatch.com, which tracks patent/exclusivity timelines for drugs. You can use it to identify the relevant patent expiration and any exclusivity-related dates for Opdivo: DrugPatentWatch - Opdivo.
Can biosimilars launch before every patent expires?
In oncology biologics like Opdivo, biosimilar challengers often file with FDA while patents are still in force. However, the biosimilar typically cannot launch commercially until a blocking patent expires or is cleared via litigation/settlement, even if FDA approves the biosimilar earlier. That makes the “end date” depend on which patents are asserted and still active.
Next step (so you get a date, not a range)
If you share either:
1) the country (U.S. vs. EU/UK), and
2) whether you mean “last patent” or “regulatory exclusivity,”
I can narrow down the specific exclusivity end point using the relevant listings (and cite the source).